J&J Q2 Revenue of $25.3B Beats Expectations, Full-Year Guidance Raised
Alina Collins
Johnson & Johnson posted Q2 revenue of $25.31 billion, up 6.6% year-over-year and above the Street's ~$25.05 billion consensus; the company raised full-year sales and earnings guidance, signaling that its newer drug pipeline is successfully replacing patent-expired products.
Where exactly did J&J beat?
Q2 revenue came in at $25.31 billion, topping the consensus ~$25.05 billion; adjusted EPS of $2.90 beat the expected $2.85.
Management raised full-year guidance: midpoint sales target lifted from $100.8 billion to $101.1 billion, EPS midpoint from $11.55 to $11.68.
This means → the beat is not just one good quarter — leadership is confident enough to pull the full-year bar higher.
What is driving the pharma segment?
The pharmaceutical division posted $16.38 billion in sales, above the $16.1 billion estimate — the main engine behind the overall beat.
The standout is immunology drug Tremfya, whose sales surged 72.5% year-over-year to $2.0 billion, far exceeding the $1.74 billion estimate. In plain terms = J&J's legacy psoriasis blockbuster Stelara is losing patent protection and shrinking; Tremfya is picking up the baton — and doing it much faster than the market expected.
Newly launched oral psoriasis treatment Icotyde reached over 11,000 patients in its first full quarter; CFO Joseph Wolk called its trajectory "extraordinary" and predicted it would generate "billions in revenue."
Why did the devices segment lag?
The MedTech division reported $8.93 billion, up 4.5% year-over-year but slightly below estimates.
The drag came from Abiomed — its Impella heart pump (a miniature device that assists blood flow during high-risk cardiac procedures) saw sales fall 2% year-over-year, a sharp reversal from 14% growth the prior quarter. This reflects a UK clinical study that raised questions about the pump's effectiveness, directly dampening physician adoption.
Management expects new data releases in the first half of next year to address the concerns, and plans to spin off the slower-growing orthopedics business to sharpen its focus.
What does this signal for Big Pharma?
J&J typically reports ahead of peers and is viewed as a bellwether for the large-cap pharma sector. This means → a beat-and-raise from J&J sets a cautiously optimistic tone heading into the rest of earnings season.
J&J shares have rallied over 60% in the past year, reflecting the market's growing confidence in its growth transition.
Despite recent operational turbulence at the FDA and pricing agreements between drugmakers and the White House, large-cap pharma has shown resilient earnings — whether peers can sustain this trend is the market's next checkpoint.
Content is for reference only, not financial advice.